Trial Outcomes & Findings for PreHospital Air Medical Plasma Trial (NCT NCT01818427)
NCT ID: NCT01818427
Last Updated: 2021-04-08
Results Overview
All cause 30 day mortality using imputation for those with missing 30 day mortality.
COMPLETED
PHASE3
523 participants
30 days
2021-04-08
Participant Flow
Participant milestones
| Measure |
Plasma
infusion of 2 units of plasma
infusion of 2 units of plasma: infusion of 2 units of plasma
|
Standard Air Medical Care
control group
|
|---|---|---|
|
Overall Study
STARTED
|
239
|
284
|
|
Overall Study
COMPLETED
|
230
|
271
|
|
Overall Study
NOT COMPLETED
|
9
|
13
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
PreHospital Air Medical Plasma Trial
Baseline characteristics by cohort
| Measure |
Plasma
n=230 Participants
infusion of 2 units of plasma
infusion of 2 units of plasma: infusion of 2 units of plasma
|
Standard Air Medical Care
n=271 Participants
control group
|
Total
n=501 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
44 years
n=99 Participants
|
46 years
n=107 Participants
|
45 years
n=206 Participants
|
|
Sex: Female, Male
Female
|
66 Participants
n=99 Participants
|
71 Participants
n=107 Participants
|
137 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
164 Participants
n=99 Participants
|
200 Participants
n=107 Participants
|
364 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
14 Participants
n=99 Participants
|
29 Participants
n=107 Participants
|
43 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
207 Participants
n=99 Participants
|
228 Participants
n=107 Participants
|
435 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
9 Participants
n=99 Participants
|
13 Participants
n=107 Participants
|
22 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
230 Participants
n=99 Participants
|
271 Participants
n=107 Participants
|
501 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: 30 daysPopulation: 10 patients in each arm were lost to follow-up for 30-day mortality and 22 patients total, 8 in the plasma arm and 12 in the standard care arm withdrew consent and 1 patient in each arm was a prisoner and could not be included in the analysis cohort. We compared 30-day mortality using a two sided pooled z test with continuity correction.
All cause 30 day mortality using imputation for those with missing 30 day mortality.
Outcome measures
| Measure |
Plasma
n=220 Participants
infusion of 2 units of plasma
infusion of 2 units of plasma: infusion of 2 units of plasma
|
Standard Air Medical Care
n=261 Participants
control group
|
|---|---|---|
|
Our Primary Outcome for the Proposal Will be 30 Day Mortality
|
53 Participants
|
89 Participants
|
SECONDARY outcome
Timeframe: at twenty four hours24-hour blood transfusion requirements will be determined by recording blood volume (mls) and number of Units transfused from the time of trauma bay arrival or upon completion of pre-hospital initiated plasma infusion. For survival bias analysis, volumes and number of blood transfusion Units received at 3, 6, 12, and 18 hours will also be recorded.
Outcome measures
| Measure |
Plasma
n=230 Participants
infusion of 2 units of plasma
infusion of 2 units of plasma: infusion of 2 units of plasma
|
Standard Air Medical Care
n=271 Participants
control group
|
|---|---|---|
|
Twenty Four-Hour Blood Transfusion Requirements
|
3 units of blood
Interval 0.0 to 7.0
|
4 units of blood
Interval 1.0 to 9.0
|
SECONDARY outcome
Timeframe: during hospitalizationIn hospital mortality will be prospectively recorded from the time of trauma bay arrival. Over the first 24 hours we will document and record the time of death in hours, while after the 24 hour time point, we will document and record the time of death in days from arrival. We suspect that patients in hemorrhagic shock will have a significant percentage of mortality occurring in the first 24 hour period.
Outcome measures
| Measure |
Plasma
n=230 Participants
infusion of 2 units of plasma
infusion of 2 units of plasma: infusion of 2 units of plasma
|
Standard Air Medical Care
n=271 Participants
control group
|
|---|---|---|
|
In-hospital Mortality
|
51 Participants
|
88 Participants
|
SECONDARY outcome
Timeframe: during hospitalizationOrgan dysfunction will be evaluated via a well-validated scoring system referred to as the Multiple Organ Dysfunction Score (MODScore). Patients who are never admitted to the ICU or those with a length of ICU stay of less than 48 hours will be considered to have a MODScore of 0. A summary of the MODScore may be calculated by summing the worst scores of each of the individual systems over the course of the ICU stay (Table 1). A summary MODScore \> 5 will be classified as multiple organ failure (MOF). Scores will be determined daily up until post injury day 28 or ICU discharge.
Outcome measures
| Measure |
Plasma
n=230 Participants
infusion of 2 units of plasma
infusion of 2 units of plasma: infusion of 2 units of plasma
|
Standard Air Medical Care
n=271 Participants
control group
|
|---|---|---|
|
Multiple Organ Failure
|
145 Participants
|
156 Participants
|
SECONDARY outcome
Timeframe: hospitalizationDevelopment of ALI will be assessed which includes: 1) bilateral infiltrates on chest x-ray, 2) a capillary wedge pressure \< 18mmHg, and 3) Pao2/Fio2 ratio \< 300 via blood gas analysis. In those patients without a Swan-Ganz catheter to determine capillary wedge pressure, the absence of signs of, or clinical concern, for elevated left sided atrial pressures will be used for the diagnosis. All patients who remain intubated beyond the first 24 hours post-injury will be evaluated using blood gas analysis and chest x-ray evaluation. Those patients who remain intubated at 48 hours through 7 days will be reevaluated for this outcome at these time points. The diagnosis of TRALI will be defined as when ALI occurs within the first 6 hours from arrival at the trauma center as it is clinically defined.
Outcome measures
| Measure |
Plasma
n=230 Participants
infusion of 2 units of plasma
infusion of 2 units of plasma: infusion of 2 units of plasma
|
Standard Air Medical Care
n=271 Participants
control group
|
|---|---|---|
|
Acute Lung Injury (ALI) and Transfusion Related Acute Lung Injury (TRALI)
|
48 Participants
|
50 Participants
|
Adverse Events
Plasma
Standard Air Medical Care
Serious adverse events
| Measure |
Plasma
n=220 participants at risk
infusion of 2 units of plasma
infusion of 2 units of plasma: infusion of 2 units of plasma
|
Standard Air Medical Care
n=261 participants at risk
control group
|
|---|---|---|
|
Blood and lymphatic system disorders
tranfusion-related reaction
|
0.45%
1/220 • Number of events 1 • 30 days
|
0.00%
0/261 • 30 days
|
|
Blood and lymphatic system disorders
sepsis
|
0.00%
0/220 • 30 days
|
0.38%
1/261 • Number of events 1 • 30 days
|
|
Respiratory, thoracic and mediastinal disorders
adult respirator distress syndrome
|
0.00%
0/220 • 30 days
|
0.38%
1/261 • Number of events 1 • 30 days
|
Other adverse events
| Measure |
Plasma
n=220 participants at risk
infusion of 2 units of plasma
infusion of 2 units of plasma: infusion of 2 units of plasma
|
Standard Air Medical Care
n=261 participants at risk
control group
|
|---|---|---|
|
Blood and lymphatic system disorders
allergic reation
|
0.91%
2/220 • Number of events 2 • 30 days
|
0.00%
0/261 • 30 days
|
|
Blood and lymphatic system disorders
Anaphylaxis
|
0.45%
1/220 • Number of events 1 • 30 days
|
0.00%
0/261 • 30 days
|
|
Blood and lymphatic system disorders
fever
|
0.00%
0/220 • 30 days
|
0.38%
1/261 • Number of events 1 • 30 days
|
|
Blood and lymphatic system disorders
hypotension
|
0.45%
1/220 • Number of events 1 • 30 days
|
0.00%
0/261 • 30 days
|
|
Blood and lymphatic system disorders
pain
|
0.00%
0/220 • 30 days
|
0.38%
1/261 • Number of events 1 • 30 days
|
|
Blood and lymphatic system disorders
urticaria
|
0.45%
1/220 • Number of events 1 • 30 days
|
0.00%
0/261 • 30 days
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place